Puretech Health’s (PRTC) Buy Rating Reiterated at Peel Hunt
Puretech Health (LON:PRTC)‘s stock had its “buy” rating restated by stock analysts at Peel Hunt in a report released on Thursday. They presently have a GBX 278 ($3.72) price objective on the stock. Peel Hunt’s price target would indicate a potential upside of 120.20% from the company’s previous close.
PRTC has been the subject of several other reports. Numis Securities reiterated a “buy” rating and issued a GBX 207 ($2.77) price objective on shares of Puretech Health in a report on Monday, September 25th. Jefferies Group reiterated a “buy” rating and issued a GBX 225 ($3.01) price objective on shares of Puretech Health in a report on Wednesday, August 30th. N+1 Singer reiterated a “buy” rating on shares of Puretech Health in a report on Monday, September 25th. Finally, Liberum Capital reiterated a “buy” rating and issued a GBX 248 ($3.32) price objective on shares of Puretech Health in a report on Wednesday, August 30th. Five investment analysts have rated the stock with a buy rating, The company currently has an average rating of “Buy” and an average target price of GBX 248 ($3.32).
Puretech Health (PRTC) traded up GBX 1.88 ($0.03) during trading on Thursday, hitting GBX 126.25 ($1.69). 243,476 shares of the stock traded hands, compared to its average volume of 41,921. Puretech Health has a twelve month low of GBX 110 ($1.47) and a twelve month high of GBX 139 ($1.86).
Puretech Health Company Profile
PureTech Health plc is a cross-disciplinary healthcare company. The Company operates through two segments: growth stage businesses and project phase businesses. Businesses in the growth stage businesses segment are those whose activities focus on developing products to solve healthcare problems in varied markets.
Receive News & Ratings for Puretech Health PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puretech Health PLC and related companies with MarketBeat.com's FREE daily email newsletter.